Peroxisome Proliferator-Activated Receptor (PPAR)&bgr; /&dgr;: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome

Publisher： Bentham Science Publishers

E-ISSN： 1874-4702|2|1|46-55

ISSN： 1874-4672

Source： Current Molecular Pharmacology, Vol.2, Iss.1, 2009-01, pp. : 46-55

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases

By Bedu Elodie   Wahli Walter   Desvergne Béatrice  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 4, 2005-08 ,pp. : 861-873

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future

By van Raalte Daniel H.   Li Min   Pritchard P. Haydn   Wasan Kishor M.  

Pharmaceutical Research, Vol. 21, Iss. 9, 2004-09 ,pp. : 1531-1538

Springer Publishing Company

Access to resources Recommend Favorite

Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome

By  

Medicinal Chemistry, Vol. 12, Iss. 1, 2016-02 ,pp. : 3-21

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor Agonists as Potential Therapeutic Agents in Multiple Sclerosis

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 11, 2007-11 ,pp. : 1129-1135

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

By  

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1119-1124

Bentham Science Publishers

Access to resources Recommend Favorite